13M

13M is a San Francisco-based biotechnology company pioneering the discovery of small molecule drugs that target RNA structures. Founded by Dr. Hani Goodarzi of UCSF, the company utilizes a proprietary platform to identify functional RNA motifs that drive disease, particularly in oncology. Unlike traditional approaches that target proteins, 13M focuses on the complex three-dimensional shapes of RNA to unlock previously undruggable pathways. The company is backed by prominent venture capital firms like 8VC and is currently in the pre-clinical stage of development. Its approach combines advanced computational modeling with high-throughput screening to discover highly selective RNA-binding ligands.